Sarcopenia, peripheral neuropathy, and peripheral arterial disease in patients with diabetes mellitus under hemodialysis

  • Martha Beatriz Bustamante Hernández Facultad de Medicina, Universidad Autónoma del Estado de México (UNAM), Ciudad de México, México
  • José de Jesús Garduño García Facultad de Medicina, Universidad Autónoma del Estado de México (UNAM), Ciudad de México, México
  • Laura Patricia Montenegro Morales Facultad de Química, Universidad Autónoma del Estado de México (UNAM), Ciudad de México, México
  • Eneida del Socorro Camarillo Romero Facultad de Química, Universidad Autónoma del Estado de México (UNAM), Ciudad de México, México
  • Gerardo Huitrón Bravo Facultad de Medicina, Universidad Autónoma del Estado de México (UNAM), Ciudad de México, México
  • María del Socorro Camarillo Romero Facultad de Química, Universidad Autónoma del Estado de México (UNAM), Ciudad de México, México
Keywords: sarcopenia, peripheral neuropathy, peripheral arterial disease, diabetes mellitus, renal dialysis, hemodialysis

Abstract

Introduction: Sarcopenia is characterized by loss of strength and muscle mass. Patients with diabetes mellitus who are under hemodialysis treatment show decreased physical activity and changes in their food intake, which also leads to the presence of sarcopenia. On the other hand, peripheral neuropathy and peripheral arterial disease commonly appear as chronic complications of diabetes mellitus. Methods: A cross-sectional, observational study was carried out in diabetes mellitus patients on hemodialysis. For the assessment of sarcopenia, muscle strength, physical performance and muscle mass percentage were measured. Muscle strength was calculated with a dynamometer, while physical performance was evaluated in seconds by means of a walk test with a stopwatch; muscle mass percentage was obtained using a scale with bioelectrical impedance. Sarcopenia was considered severe when there was low muscle strength and percentage in addition to low physical performance. Peripheral neuropathy was assessed by exploring touch and pressure sensibility with the Semmes-Weinstein monofilament test and deep sensibility with a 128 Hz tuning fork. The ankle-brachial index was the measurement taken for the peripheral arterial disease classification. Results: The final analysis was performed with 33 patients, whose time on hemodialysis was 3.57 ± 2.56 years. The prevalence of severe sarcopenia and sarcopenia was 90.8% and that of pre-sarcopenia was 9% of all patients. On the other hand, 78.1% were found to be patients with loss of deep sensibility, while the percentage of patients with loss of sensibility to pressure and touch was 54.5%. A correlation was found between the sarcopenia parameters and the time of evolution of renal failure and age. Conclusion: Sarcopenia occurs, in its different stages, in practically all diabetes mellitus patients undergoing hemodialysis; there is a relationship with the patient's age and hemodialysis time.

References

Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147(8):755-63. doi: 10.1093/oxfordjournals.aje.a009520.

Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, Guralnik J, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): screening, Diagnosis and Management. J Nutr Health Aging. 2018;22(10):1148-61. doi: 10.1007/s12603-018-1139-9.

Sakuma K, Aoi W, Yamaguchi A. Current understanding of sarcopenia: possible candidates modulating muscle mass. Pflugers Arch. 2015;467(2):213-29. doi: 10.1007/s00424-014-1527-x.

Kittiskulnam P, Carrero JJ, Chertow GM, Kaysen GA, Delgado C, Johansen KL. Sarcopenia among patients receiving hemodialysis: weighing the evidence. J Cachexia Sarcopenia Muscle. 2017;8(1):57-68. doi: 10.1002/jcsm.12130.

Cusumano AM. Sarcopenia en pacientes con y sin insuficiencia renal crónica: diagnóstico, evaluación y tratamiento. Rev Nefrol Dial Traspl. 2015;35(1):32-3.

Veronese N, Pizzol D, Demurtas J, Soysal P, Smith L, Sieber C, et al. Association between sarcopenia and diabetes: a systematic review and meta-analysis of observational studies. Eur Geriatr Med. 2019;10(5):685-96. doi: 10.1007/s41999-019-00216-x.

Kim YK, Lee HS, Ryu JJ, In Lee H, Seo SG. Sarcopenia increases the risk for mortality in patients who undergo amputation for diabetic foot. J Foot Ankle Res. 2018;11:32. doi: 10.1186/s13047-018-0274-1.

Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al.; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. doi: 10.1093/ageing/afy169.

Dive D, Lievens I, Moonen G, Wang FC. La neuropathie diabétique périphérique [Diabetic peripheral neuropathy]. Rev Med Liege. 2005;60(5-6):490-7.

Alba Zayas LE, Pereira Roca G, Aguilar Betancourt A. Lipoproteína (a): estructura, metabolismo, genética y mecanismos patogénicos. Rev Cubana Invest Bioméd. 2003;22(1):32-40.

Triana Ricci R. Pie diabético. Fisiopatología y consecuencias. Nefrología (Madr.). 2014;28(4):143-53. doi: 10.1016/j.rccot.2015.04.006.

Asociación Latinoamericana de Diabetes. Guías ALAD sobre el diagnóstico, control y tratamiento de la diabetes mellitus tipo 2 con medicina basada en evidencia. Rev ALAD. 2019;(9 Supl. 1):1-119.

Escobar C, Barrios V, Manzano L. Relevancia de la enfermedad arterial periférica en sujetos de edad avanzada. Hipertens Riesgo Vasc. 2012;29(1):14-21. doi: 10.1016/j.hipert.2011.12.001.

Serrano Hernando FJ, Martín Conejero A. Enfermedad arterial periférica: aspectos fisiopatológicos, clínicos y terapéuticos. Rev Esp Cardiol. 2007;60(9):969-82. doi: 10.1157/13109651.

Adam DJ, Bradbury AW. TASC II Document on the Management of Peripheral Arterial Disease. Eur J Vasc Endovasc Surg. 2007;33(1):1-2). doi: 10.1016/j.ejvs.2006.11.008.

Lechuga Domínguez MJ, Rodríguez García A, Vázquez Caridad EM. Análisis de los factores influyentes en la prevalencia de las úlceras de pie en pacientes en hemodiálisis. Enferm Nefrol. 2017;20(2):101-11. doi: 10.4321/s2254-288420170000200002.

Schaper NC, van Netten JJ, Apelqvist E, Sicco A, Hinchliffe RJ, Lipsky BA. Directrices IWGDF en la prevención y tratamiento de la enfermedad del pie diabético [Internet]. Bruselas: International Working Group on the Diabetic Foot, 2019. 194 p. Disponible en: https://iwgdfguidelines.org (consulta: 23-07-2020).

Sousa-Santos AR, Amaral TF. Differences in handgrip strength protocols to identify sarcopenia and frailty - a systematic review. BMC Geriatr. 2017;17(1):238. doi: 10.1186/s12877-017-0625-y.

Abro A, Delicata LA, Vongsanim S, Davenport A. Differences in the prevalence of sarcopenia in peritoneal dialysis patients using hand grip strength and appendicular lean mass: depends upon guideline definitions. Eur J Clin Nutr. 2018;72(7):993-999. doi: 10.1038/s41430-018-0238-3.

Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. doi: 10.1093/ageing/afy169.

Mori K, Nishide K, Okuno S, Shoji T, Emoto M, Tsuda A, et al. Impact of diabetes on sarcopenia and mortality in patients undergoing hemodialysis. BMC Nephrol. 2019;20(1):105. doi: 10.1186/s12882-019-1271-8.

Mesinovic J, Zengin A, De Courten B, Ebeling PR, Scott D. Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. Diabetes Metab Syndr Obes. 2019;12:1057-72. doi: 10.2147/DMSO.S186600.

Yasemin Ö, Seydahmet A, Özcan K. Relationship between diabetic neuropathy and sarcopenia. Prim Care Diabetes. 2019;13(6):521-8. doi: 10.1016/j.pcd.2019.04.007.

Kittiskulnam P, Chertow GM, Carrero JJ, Delgado C, Kaysen GA, Johansen KL. Sarcopenia and its individual criteria are associated, in part, with mortality among patients on hemodialysis. Kidney Int. 2017;92(1):238-47. doi: 10.1016/j.kint.2017.01.024.

Harada H, Ikeda H, Nishiyama Y, Niiyama H, Katoh A, Kai H. Increased arterial velocity pulse index is an independent factor related to skeletal muscle mass reduction and tissue damage in patients with cardiovascular disease. Hypertension Res. 2020;43(6):534-42. doi: 10.1038/s41440-020-0404-6.

Oh TJ, Kang S, Lee JE, Moon JH, Choi SH, Lim S, et al. Association between deterioration in muscle strength and peripheral neuropathy in people with diabetes. J Diabetes Complications. 2019;33(8):598-601. doi: 10.1016/j.jdiacomp.2019.04.007.

Tian SL, Zhang K, Xu PC. Increased prevalence of peripheral arterial disease in patients with obese sarcopenia undergoing hemodialysis. Exp Ther Med. 2018;15(6):5148-52. doi: 10.3892/etm.2018.6002.

Lera L, Ángel B, Sánchez H, Picrin Y, Hormazabal MJ, Quiero A, et al. Estimación y validación de puntos de corte de índice de masa muscular esquelética para la identificación de sarcopenia en adultos mayores chilenos. Nutr Hosp. 2015;31(3):1187-97. doi: 10.3305/nh.2015.31.3.8054.

Villada-Gómez JS, González-Correa CH, Marulanda-Mejía F. Puntos de corte provisionales para el diagnóstico de sarcopenia en ancianos de Caldas, Colombia. Biomédica. 2018;38(4):521-6. doi: doi: 10.7705/biomedica.v38i4.4302.

Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014;15(2):95-101. doi: 10.1016/j.jamda.2013.11.025.

Yang Q, Zhang Y, Zeng Q, Yang C, Shi J, Zhang C, et al. Correlation between diabetic peripheral neuropathy and sarcopenia in patients with type 2 diabetes mellitus and diabetic foot disease: a cross-sectional study. Diabetes Metab Syndr Obes. 2020;13:377-86. doi: 10.2147/DMSO.S237362.

Tavakoli M, Gogas Yavuz D, Tahrani AA, Selvarajah D, Bowling FL, Fadavi H. Diabetic neuropathy: current status and future prospects. J Diabetes Res. 2017;2017:5825971. doi: 10.1155/2017/5825971.

Beckert S, Sundermann K, Wolf S, Königsrainer A, Coerper S. Haemodialysis is associated with changes in cutaneous microcirculation in diabetes mellitus. Diabet Med. 2009;26(1):89-92. doi: 10.1111/j.1464-5491.2008.02610.x.

Castro-Sánchez AM, Moreno-Lorenzo C, Matarán-Peñarrocha GA, Feriche-Fernández-Castanys B, Sánchez Labraca N, et al. Eficacia de un programa de masaje y ejercicio sobre el índice tobillo/brazo y presión sanguínea en pacientes con diabetes mellitus tipo 2 y enfermedad arterial periférica: ensayo clínico aleatorizado. Med Clin (Barc). 2010;134(3):107-10. doi: 10.1016/j.medcli.2009.07.018.

Sheng K, Zhang P, Chen L, Cheng J, Wu C, Chen J. Intradialytic exercise in hemodialysis patients: a systematic review and meta-analysis. Am J Nephrol. 2014;40(5):478-90. doi: 10.1159/000368722.

Qiu Z, Zheng K, Zhang H, Feng J, Wang L, Zhou H. Physical exercise and patients with chronic renal failure: a meta-analysis. Biomed Res Int. 2017;2017:7191826. doi: 10.1155/2017/7191826.

Published
2021-09-21
How to Cite
1.
Bustamante Hernández MB, Garduño García J de J, Montenegro Morales LP, Camarillo Romero E del S, Bravo GH, Camarillo Romero M del S. Sarcopenia, peripheral neuropathy, and peripheral arterial disease in patients with diabetes mellitus under hemodialysis. Rev Nefrol Dial Traspl. [Internet]. 2021Sep.21 [cited 2024Jul.16];41(3):151-8. Available from: http://revistarenal.org.ar/index.php/rndt/article/view/679
Issue
Vol. 41 No. 3 (2021): Jul.-Sept.
Section
Original Article

Copyright (c) 2021 Revista de Nefrología, Diálisis y Trasplante

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.